PC-specific mortality. However, the risk for PC progression on primary ADT was not studied. The likely explanation for the 40 % decline in PCspecific mortality during this time period is earlier detection and definitive curative intervention. ADT is not curative. This study re-affirms that ADT should be reserved for its established role: as palliation for metastatic PC, in men with node-positive PC after RP, or in combination with RT in intermediate-or high-risk PC. 8, 9 The treatment options for low-risk and very-low-risk patients include AS, WW, or monotherapies such as interstitial prostate brachytherapy, RT,
Prostate cancer (PC) is the second most common malignancy in American men and the second leading cause of cancer-related death in men in the US.
It is estimated that in 2014 nearly 233,000 men will be diagnosed with PC, with 29,480 dying from the disease. 1, 2 The majority of them are diagnosed as a result of screening, so symptomatic presentation is unusual. Since the introduction of prostate-specific antigen (PSA) screening in US, more than 1.3 million men have been diagnosed with PC and one million of these have undergone treatment. 3 Over 95 % of PCs are adenocarcinomas and the median age at diagnosis is 66 years. As per the Surveillance, Epidemiology, and End Results (SEER) 18 database, 80 % have localized disease and only 12 % have regional disease at diagnosis. In the same database, 5-year survival rates vary significantly with stage and have been noted to be 100 % for localized and regional stage disease. The risk factors for PC are increasing age, African American descent, and a family history of PC.
Localized Prostate Cancer
The Several studies have shown that patients with low-grade, localized PC have a low risk for clinical progression within the first 10 to 15 years of diagnosis, so AS and WW are reasonable options. This strategy is also best suited to men with a shorter life expectancy. [4] [5] [6] [7] First-line ADT is seldom indicated in patients with localized PC. The outcomes of men treated with primary ADT, compared with those who
were not, was evaluated in a large, retrospective cohort study. ADT is not associated with increased risk for all-cause mortality, or with reduced
OncOlOgy & HematOlOgy Review and RP, depending on the life expectancy. The data do not provide clearcut evidence for the superiority of one over another. Hence, a balanced discussion, carefully weighing the risks and benefits, and making a decision after factoring in patient and physician choices, is reasonable.
Radical Prostatectomy in Localized Disease
The role of RP was evaluated by two randomized clinical trials (RCTs) in the pre-PSA era. In both these studies, RP was compared with observation. The updated results from the Veterans' Administration Cooperative Urological
Research Group (VACURG), reporting after 20 years of follow-up, failed to show a difference in mortality. 10 In contrast to this, the recently reported Clinically localized tumors with adverse prognostic features can be completely excised with RP and pelvic LND, leaving patients with a reasonable life expectancy. Studies have reported that patients with adverse prognostic features (T3, GS 8-10, PSA >20) had a better OS survival and lower risk for metastatic progression and PC-specific mortality with RP compared with RT, suggesting RP may be a viable alternative for patients who are not candidates for RT or who prefer surgery.
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The gold standard for surgery is open retropubic RP (RRP); however, this option is invasive with inherent morbidity associated with it. Therefore, patients and surgeons alike have sought out less-invasive surgical options, one of which is robotic-assisted laparoscopic RP (RALP).
The Robotic-assisted Laproscopic Radical Prostatectomy Approach
The RALP approach has been rapidly adopted since it was introduced in 2000 and is currently the most common approach to RP, accounting for The primary challenge associated with low-risk PC is often an overtreatment of disease, while for high-risk PC it is undertreatment. Many patients with high-risk disease who are likely to benefit from aggressive local therapy with curative intent only receive palliative treatment with ADT. Single modality therapies are less effective in this population.
Role of Andogen Deprivation Therapy with Radiation Therapy in Localized and Locally Advanced Prostate Cancer
Single modality treatments given to high-risk patients with a curative intent have resulted in poor responses and high clinical and biochemical failures (>50 % at 5 years). These poor outcomes are observed irrespective of the primary treatment modality. Given these results, a combined approach was explored. The rationale of the combined approach is that the addition of ADT slows the progression of the tumor by eliminating the hormonal stimulus that drives cancer cell proliferation. In vivo animal models have shown that the combined effect of ADT and RT increases overall cell kill and diminishes growth velocity of the surviving cancer cells. 
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EORTC 22961 compared 6 months of ADT to 3 years in locally advanced PC patients. In this study, short-term ADT was also associated with inferior survival. 26 Based on these data and the meta-analysis of RTOG trials, 27 the PC patients with high-grade (GS of 8-10) and/or locally advanced disease (T3,T4,N+) who were treated with RT, derived survival benefit with longterm ADT administration.
Several studies have evaluated the threshold for the duration of neoadjuvant ADT (NADT) prior to RT. RTOG 96-01 compared 6 months to 3 months. The 10-year updated results showed that 6-month ADT decreased distant progression, PC-specific mortality, and all-cause mortality, compared with RT alone. In this study, no increase in treatmentrelated morbidity was noted in the first 5 years after randomization. The 3-month ADT has not demonstrated similar benefit. 28 So, neoadjuvant hormone therapy (NHT) given for less than 6 months appears to be suboptimal for survival benefit in patients with intermediate-to high-risk PC. However, in the All Ireland Cooperative Oncology Research Group and Canadian study, no difference in OS and patterns of failure was noted with longer NHT duration. 29, 30 Similarly, in intermediate-risk clinically localized patients, 6 months of ADT along with RT, resulted in a significantly higher survival rate, lower PCspecific mortality, and higher survival free of salvage ADT. No significant difference in the risks for systemic progression or PC deaths was observed with RT + ADT and RRP. The risk for all-cause mortality, however, was greater with RT plus ADT than after RRP (HR, 1.60; 95 % CI, 1.25-2.05; p=0.0002). 33 In men with high-risk tumors (GS ≥8 or PSA >10), both overall and PC-specific mortality were statistically significantly lower in the group that underwent RP than the group that received RT. In men with low-risk tumors (GS ≤6 and PSA ≤10), there was no difference in PC-specific mortality and a modest but statistically significant difference in overall mortality. Intermediate risk patients are not included in this analysis. The study results are not conclusive due to differences in patient characteristics with the older age and higher incidence of comorbidities in the radiation therapy group. In addition, patients with higher stage and grade of cancer are likely to receive RT, hence influencing the outcomes. Proper randomized comparison between the two modalities can be used to judge which treatment might be superior. 34 The Prostate Testing for Cancer and Treatment (ProtecT)
OncOlOgy & HematOlOgy Review trial is currently evaluating prospectively the survival outcomes of AS, RP, and RT in localized PC.
The role of escalated dose RT was evaluated in the randomized trials, [35] [36] [37] [38] as noted in Table 1 . These confirmed that it mainly improved biochemical relapse (BCR) rate and biochemical progression-free survival (PFS), but had no significant impact on OS.
Chemotherapy in the Management of High-risk Localized Disease
Chemotherapy and other systemic agents were used in the adjuvant setting to target the micrometastatic disease and androgen-resistant clones. Several agents were evaluated in combination with ADT and RT in adjuvant and neoadjuvant sequences (see Table 2 ).
RTOG 99-02 was closed after 4 years, due to excessive thromboembolic events and a significant increase in hematologic and GI toxicity in the adjuvant chemo arm. Long-term complications with myelodysplasia/ acute myelogenous leukemia were noted in three patients. 39 We await the final results of the RTOG 0521 study, which will certainly help to NCT01546987 is a phase III trial currently recruiting high-risk PC patients to evaluate the addition of steroid 17alpha-monooxygenase TAK-700 to dose-escalated RT and standard ADT.
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate
Cancer and High-risk Features of Relapse (PEACE2) is a randomized study currently recruiting patients with high-risk localized PC to evaluate whether the addition of cabazitaxel to standard ADT + RT will improve the clinical PFS. 41 The treatment of PC does not end with treatment selection; the biochemical response is crucial to evaluate the response, and is delineated below.
The Role of PSA Nadir in Androgen Deprivation Therapy + External Beam Radiation Therapy
The biochemical response to ADT, and/or RT, is called the 'PSA nadir'
(lowest value after treatment) and is useful in predicting outcome and help to guide therapy. Biochemical DFS was significantly higher for patients with a nearly complete biochemical response, as indicated by the pre-RT, post-ADT PSA level.
D'Amico et al. performed a systematic review of two RCTs using the Prentice criteria to assess whether PSA nadir or PSA end concentrations >0.5 ng/ml were surrogates for PC-specific mortality. It is noted that men who received a combination of RT and 6 months of ADT were significantly less likely to have both these PSA values >0.5 ng/ml compared with years, failure to obtain a PSA-CR has a significantly worse disease-specific survival (DSS), DFS, higher incidence of distant metastasis, and biochemical failure. The authors concluded that this will help identify patients who may
benefit from the addition of long-term androgen ablation. There is also a need to better define cancer progression. 45, 46 Routine postcryotherapy biopsies are not recommended because of the high negative biopsy rate. However, if PSA is rising, prostate biopsy can be performed, and those patients with positive biopsies be retreated. PSA failures after TFT have the option of additional treatment with cryotherapy, prostatectomy, or RT. 44 Prostatectomy patients have incontinence rates of 6 % and impotency of 30 % and can take up to 2 years for return of potency after surgery. 47 Impotence rates after hemigland cryoablation range from 10-30 % and may take up to 1 year after treatment for return of potency. 47 Individuals on hormones may experience a longer period before the return of potency. Fistula formation was one of the main concerns with cryotherapy in the 1990s and the incidence in the current literature ranges between 0 % and 0.5 %, which is similar to rectal injury after RRP. 46 Other modalities uses for TFT are high-intensity focal ultrasound (HIFU), where tissue destruction is produced by thermal, mechanical, and cavitation effects with coagulative necrosis. Adequate cell destruction can be produced by short exposure to temperatures of 60°C or more.
Most of the data is from case series. surgical margin, and lymph node status). PSA doubling time (PSADT) is the most important prognostic factor for metastasis-free survival and OS. [48] [49] [50] [51] It is important for these patients to undergo complete staging evaluation to rule out metastatic progression prior to subjecting them to any therapy. Conventional imaging with computed tomography (CT) and bone scans is unlikely to reveal metastatic disease at low PSA levels. Immunoscintigraphy with ProstaScint scanning was used for some time to detect localized recurrence or lymphatic spread. It frequently yielded false negative results and was able to detect about 20-30 % of metastatic disease. The choline positron emission tomography-CT (PET/ CT) is an extremely sensitive test, with a low false positivity. It has the capacity to detect disease recurrence in 20 % of patients even with a PSA ≤1 ng/ml. 52 As PC is one of the most common cancers to metastasize to bone, very sensitive bone imaging is needed and the sodium fluoride PET/CT scan is noted to serve this purpose with a high sensitivity (91 %) and specificity (90 %).
BCR is a challenge, as decisions have to be made to delay the onset of metastatic disease and death while avoiding overtreatment, as this disease may never affect patients' OS or quality of life.
Management of Post-prostatectomy PSA Relapse
Recurrence usually manifests initially as PSA rise, with no radiographic evidence of cancer. In the absence of salvage therapy, the median time from PSA recurrence to distant metastasis is about 8 years. The critical concern in these patients is to determine whether a rising PSA reflects local or distant recurrence. Most are candidates for salvage RT and some can benefit from the addition of ADT. Those with unfavorable features benefit from the addition of ADT to RT. Whole pelvic RT confers superior biochemical RFS compared with prostate bed RT for high-risk patients receiving adjuvant or salvage RT along with concurrent androgen suppression. No benefit is noted in low-risk patients. 53 Stephenson et al. It consisted of 771 men with a BCR after RP who were randomized to salvage RT and 2 years of bicalutamide (150 mg) versus salvage RT alone in a double-blinded placebo-controlled trial. At a median follow-up of 7 years, there was no survival difference but a higher PSA progressionfree rate (57 % versus 40 %; p<0.0001). Lower cumulative incidence of metastatic PC (7 % versus 13 %; p<0.04) was also noted in the arm on concurrent ADT, with an increased benefit in high-risk disease. 59 What is the impact of these published RCT on referral patterns? This was evaluated in patients with high-risk features. It is noted that only 13-14 % of these high-risk patients were referred for adjuvant RT within 6 months of RP and 70 % of these patients had a PSA level of <0.2 ng/ml at the time of the referral. It is also noted that patients with higher pathologic T stage and more advanced GS are more likely to be referred. 60, 61 These poor referral patterns can be explained by the ongoing debate regarding the optimal timing of postsurgical RT and by the introduction of ultrasensitive PSA tests capable of detecting levels of <0.01 ng/ml. It remains controversial as to whether RT delivered at the earliest signs of PSA recurrence is as effective as treatment with an undetectable PSA.
Two phase III RCTs (RADICALS and RAVES) are currently being conducted to compare adjuvant versus early salvage RT. However, until the results of these trials are available, decisions for these patients should be made in a multidisciplinary fashion by both urologists and radiation oncologists to discuss the potential benefits and risks for adjuvant RT.
Natural compounds like sulforaphane (SF), which is present in cruciferous vegetables, is evaluated in post-RP PSA relapse PC patients ± adjuvant or salvage RT. This is a multicenter, double-blind, randomized, placebocontrolled study. A 78 % increase in PSADT was observed in the SF group (21.9 versus 12.1 months) compared with placebo. The mean change in PSA levels between month 6 and 0 was significantly lower in the SF group compared with placebo (0.099 ± 0.341 versus 0.620 ± 1.417 ng/ml; p=0.03). The medication was pretty well tolerated, other than some GI effects. The results were encouraging both in efficacy and safety, indicating the need for more extensive evaluation of this compound.
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Salvage Therapy Post-radiation Therapy PSA Relapse
Various options exist for salvage local treatment after the failure of RT, including surgery, additional RT, and cryotherapy.
Salvage RP after RT has the longest history and best likelihood of local control relative to other salvage treatments. 63 However, the risks for adverse events (AEs) are high with salvage RP because of the radiation-induced fibrosis and poor wound healing. The best contemporary evidence is from a retrospective, international, multi-institutional cohort analysis of 404 men with radiation-recurrent PC. Five-year BCR-free, metastasis-free, and CSS rates of 48 %, 83 %, and 92 %, were noted, respectively, with post salvage RP. Men with a GS <7 and preoperative PSA <4 ng/ml were identified as a favorable risk. Among this group of favorable patients (n=120), no PC-specific deaths were noted and BCR-free survival was 64 % at 5 years. 64 In this era of robotic surgery, the role of salvage robotic RP was also genitourinary toxicity was 13 % (0-47) and GI toxicity was 5% (0-20). 68 Higher toxicity rates might impair the widespread use of this approach.
The situation is similar with salvage cryoablation, as most studies are small retrospective series. An analysis of the COLD Registry found a biochemical DFS at 3 years of 66.7 %. 69 In this study, a pre-RT PSA <10 ng/ml, GS <8, clinical stage T1c or T2 disease, a low presalvage PSA (<5 ng ml), and a long PSADT (>16 months) are associated with a favorable response. This is similar to the results of the salvage RT studies. 70 This is an attractive alternative, but randomized trials are needed to elucidate the relative cancer control and toxicity of various options for local salvage after definitive RT.
Hormonal Therapy For PSA-recurrent Prostate Cancer
The are under study. The celecoxib-versus-placebo study was terminated due to cardiovascular concerns, despite significant improvements in PSA velocity.
In the calcifidol study, 80 % had increases in PSADT. Lapatinib caused significant reduction in the mean PSA slope, but no PSA responses. 77 Natural nonhormonal products such as pomegranate (PoMX), curcumin, Acai juice, and indole-3-carbinol are also under investigation.
PoMX is a rich source of polyphenols and is reported to have higher antioxidant potential than green tea or red wine. Bioactive compounds in PoMX juice have been shown to have dose-dependent anti-tumor activity in both in vitro cell culture and in vivo mouse model. 78 Research by Pantuck et al.
documented a significant increase in PSADT in PC patients following RP or RT for organ-confined disease. 79 Paller's study was a randomized, multicenter, double-blind phase II, dose-exploring trial, subjecting men with a rising PSA and without metastases to either 1 g or 3 g of POMx. PSADT lengthened in both groups by >6 months. Forty-two percent of patients discontinued treatment prior to the protocol-definition of PSA progression, or at 18 months, primarily due to a rising PSA. No significant changes occurred in testosterone levels. The inclusion of a placebo control arm is needed to further investigate the clinical utility of this intriguing supplement.
Muscadine grape skin (MPX) comprising ellagic acid, quercetin, and resveratrol, demonstrates preclinical activity against PC cells in vitro. Phase I data suggested that 4,000 mg of MPX is safe and it extended the PSADT by 3.9 months. 80 The phase II study is currently accruing patients.
Curcumin inhibits nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and slows PC growth in cell lines. The androgen sensitive and insensitive cell lines were exposed to curcumin and it is noted to be a potent inhibitor of epidermal growth factor-receptor (EGF-R) signaling. 81 This is accomplished by downregulation of the EGF-R protein, inhibition of the intrinsic and ligand-induced EGFR-tyrosine kinase activity.
The UK National Cancer Research Network (NCRN) Pomi-T study is a double-blind, placebo-controlled randomized trial, evaluated the effect of a polyphenol-rich whole food supplement on PSA progression in men with PC. 82 Of 199 men with localized PC, 60 % managed with primary AS or 40 % with WW following prior intervention. They were randomized in 2:1 to receive an oral capsule containing a blend of PoMX, green tea, broccoli and turmeric, or an identical placebo for 6 months. The median rise in PSA was 14.7% versus 78.5% with placebo (p=0.0008). Forty-six percent of men in the food supplement arm had stable or lower PSA at trial completion versus 14 % in the placebo arm. The supplement was well tolerated except for mild GI symptoms. This study showed short-term, favorable effect on PSA kinetics with this food supplement, but randomized trials with longterm follow-up are required to confirm this effect.
Non-metastatic Castrate-resistant Prostate Cancer
The non-metastatic castrate-resistant PC (NM-CRPC) develops mainly in the setting of the early use of ADT. NM-CRPC has a heterogeneous natural history, but can be enriched based on known predictors of PC-related morbidity and/or mortality.
ARN-509 is a novel second-generation anti-androgen that binds directly to the ligand-binding domain of the androgen receptor, impairing nuclear translocation, and DNA binding. The phase II portion of a multicenter phase I/II study evaluated the activity in high-risk NM-CRPC patients.
All patients had CRPC, no radiographic evidence of metastases (pelvic lymph nodes <3 cm below the iliac bifurcation were allowed), and high risk for disease progression based on PSA value ≥8 ng/ml within general disorders and administration site reactions. 84 The IMAAGEN core study is a phase II, multicenter study evaluating the ability of abiraterone plus prednisone to decrease PSA levels in patients with NM-CRPC with rising PSA. They have enrolled 131 patients with PSA value ≥10 ng/ml or PSADT ≤10 months at screening and 122 are evaluable.
Median age was 72 years (range 48-90) and median baseline PSA was 13.7 ng/ml (1.6-167.8 ng/ml). By the end of six cycles of treatment, 60 % (73/122) had ≥90 % PSA reduction. From these results the authors concluded that the rate and depth of PSA decline appeared superior than in men with metastatic CRPC (mCRPC).
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Conclusion
PC is heterogeneous with a variable disease course. Careful consideration needs to be made in treatment selections for our aging population. The real problem is BCR. There is no consensus regarding optimal management of this disease state. BCR should be individualized, taking into account risk stratification and prior therapy, before making a treatment decision. The benefit of the early initiation of ADT is offset by its AEs. Patients placed on surveillance face anxiety and seek interventions to delay or prevent progression to metastatic disease. However, PSA relapse represents a window of opportunity to evaluate therapies that will delay progression. Given that the majority of these patients have been pretreated with ADT, NM-CRPC is on the rise. Clinical trials should be strongly considered in the setting of BCR, especially for NM-CRPC. n
